These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23503938)

  • 1. The diagnostic utility of matrix metalloproteinase-3 and high-sensitivity C-reactive protein for predicting rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-negative patients with recent-onset undifferentiated arthritis.
    Hiura K; Iwaki-Egawa S; Kawashima T; Fujisawa S; Takeda T; Komori H; Watanabe Y
    Rheumatol Int; 2013 Sep; 33(9):2309-14. PubMed ID: 23503938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnostic utility of anti-cyclic citrullinated peptide antibodies, matrix metalloproteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and C-reactive protein in patients with erosive and non-erosive rheumatoid arthritis.
    Shovman O; Gilburd B; Zandman-Goddard G; Sherer Y; Orbach H; Gerli R; Shoenfeld Y
    Clin Dev Immunol; 2005 Sep; 12(3):197-202. PubMed ID: 16295525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
    Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
    J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis.
    Kudo-Tanaka E; Ohshima S; Ishii M; Mima T; Matsushita M; Azuma N; Harada Y; Katada Y; Ikeue H; Umeshita-Sasai M; Miyatake K; Saeki Y
    Clin Rheumatol; 2007 Oct; 26(10):1627-33. PubMed ID: 17286215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis.
    Ateş A; Karaaslan Y; Aksaray S
    Clin Rheumatol; 2007 Apr; 26(4):499-504. PubMed ID: 16670828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performance of anti-cyclic citrullinated peptide and rheumatoid factor in patients with rheumatoid arthritis.
    Chang PY; Yang CT; Cheng CH; Yu KH
    Int J Rheum Dis; 2016 Sep; 19(9):880-6. PubMed ID: 25940989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis.
    Jansen AL; van der Horst-Bruinsma I; van Schaardenburg D; van de Stadt RJ; de Koning MH; Dijkmans BA
    J Rheumatol; 2002 Oct; 29(10):2074-6. PubMed ID: 12375314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnostic utility of anti-cyclic citrullinated peptide antibody in early rheumatoid arthritis].
    Miyamura T; Watanabe H; Takahama S; Sonomoto K; Nakamura M; Ando H; Minami R; Yamamoto M; Suematsu E
    Nihon Rinsho Meneki Gakkai Kaishi; 2009 Apr; 32(2):102-9. PubMed ID: 19404008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cyclic citrullinated peptide antibodies (anti-CCP) together with some other parameters used for serologic diagnosis of rheumatoid arthritis].
    Us D; Gülmez D; Hasçelik G
    Mikrobiyol Bul; 2003; 37(2-3):163-70. PubMed ID: 14593899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence and diagnostic performance of anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: the predictive and discriminative ability of serum antibody level in recognizing rheumatoid arthritis.
    Heidari B; Firouzjahi A; Heidari P; Hajian K
    Ann Saudi Med; 2009; 29(6):467-70. PubMed ID: 19847085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response.
    Verpoort KN; Jol-van der Zijde CM; Papendrecht-van der Voort EA; Ioan-Facsinay A; Drijfhout JW; van Tol MJ; Breedveld FC; Huizinga TW; Toes RE
    Arthritis Rheum; 2006 Dec; 54(12):3799-808. PubMed ID: 17133560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of anticyclic citrullinated peptide in the diagnosis of early rheumatoid factor-negative suspected rheumatoid arthritis: is it worthwhile to order the test?
    Panchagnula R; Rajiv SR; Prakash J; Chandrashekara S; Suresh KP
    J Clin Rheumatol; 2006 Aug; 12(4):172-5. PubMed ID: 16891919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis.
    Suzuki K; Sawada T; Murakami A; Matsui T; Tohma S; Nakazono K; Takemura M; Takasaki Y; Mimori T; Yamamoto K
    Scand J Rheumatol; 2003; 32(4):197-204. PubMed ID: 14626625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3 months duration) rheumatoid arthritis.
    Barouta G; Katsiari CG; Alexiou I; Liaskos C; Varna A; Bogdanos DP; Germenis AE; Sakkas LI
    Clin Rheumatol; 2017 Apr; 36(4):885-894. PubMed ID: 27943044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Predictive values of anti-cyclic citrullinated peptide antibody, antikeratin antibody and rheumatoid factor in diagnosing articular erosions in patients with rheumatoid arthritis].
    Xie QB; Yin G
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):508-12. PubMed ID: 19627016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.
    Schellekens GA; Visser H; de Jong BA; van den Hoogen FH; Hazes JM; Breedveld FC; van Venrooij WJ
    Arthritis Rheum; 2000 Jan; 43(1):155-63. PubMed ID: 10643712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New biomarkers for rheumatoid arthritis].
    Hayashi N; Nishimura K; Kumagai S
    Rinsho Byori; 2008 Apr; 56(4):297-308. PubMed ID: 18516964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study.
    Bizzaro N; Bartoloni E; Morozzi G; Manganelli S; Riccieri V; Sabatini P; Filippini M; Tampoia M; Afeltra A; Sebastiani G; Alpini C; Bini V; Bistoni O; Alunno A; Gerli R;
    Arthritis Res Ther; 2013 Jan; 15(1):R16. PubMed ID: 23339296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis.
    Greiner A; Plischke H; Kellner H; Gruber R
    Ann N Y Acad Sci; 2005 Jun; 1050():295-303. PubMed ID: 16014545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.